Alagille syndrome is a genetic disorder that affects the liver, heart, and several other organ systems. It occurs in roughly 1 in 30,000 live births, though many milder cases go unrecognized. The condition stems from a problem with how bile ducts develop in the liver, leading to a buildup of bile that can cause intense itching, jaundice, and long-term liver damage. Because it touches so many parts of the body, Alagille syndrome often looks different from one person to the next.
The Genetic Cause
Alagille syndrome is caused by mutations in genes that control a critical cell-signaling pathway called Notch signaling. About 94% of patients have a mutation in a gene called JAG1, while a smaller subset (around 2.5%) have a mutation in a gene called NOTCH2. Both genes play a role in the same signaling chain, which is why mutations in either one can produce the same syndrome.
The condition follows an autosomal dominant pattern, meaning a child only needs one copy of the mutated gene to be affected. A parent with the mutation has a 50% chance of passing it on with each pregnancy. However, roughly 50 to 70% of cases arise from new, spontaneous mutations, meaning neither parent carries the gene. This partly explains why the syndrome often appears in families with no prior history of it. Notably, when researchers screened relatives of known patients, 47% of those carrying the mutation didn’t meet the full clinical criteria for diagnosis, showing just how variable the condition can be even within the same family.
How It Affects the Liver
The hallmark of Alagille syndrome is a shortage of bile ducts inside the liver, a finding called bile duct paucity. Normally, the ratio of bile ducts to portal tracts (the small structural units where ducts should be) falls between 0.9 and 1.8. In Alagille syndrome, that ratio drops below 0.5. Fewer ducts mean bile can’t drain properly, so it backs up into the liver and eventually spills into the bloodstream.
This bile buildup, called cholestasis, drives many of the most noticeable symptoms. Jaundice (yellowing of the skin and eyes) is common in infancy. Cholesterol that would normally be excreted in bile accumulates instead, sometimes forming fatty deposits under the skin called xanthomas. But the single most burdensome symptom for many patients is relentless itching (pruritus) caused by bile acids circulating in the blood. This itching can develop early in life and become severe enough to disrupt sleep, concentration, and daily functioning.
Bile duct paucity isn’t always detectable at birth. Because bile ducts continue to develop after birth, the shortage may not show up on a liver biopsy taken before six months of age. In young children, certain lab values can signal a more severe course. Total bilirubin above 6.5 mg/dL, conjugated bilirubin above 4.5 mg/dL, or cholesterol above 520 mg/dL before age five have all been identified as predictors of sustained, more serious liver disease.
Heart and Blood Vessel Involvement
Heart defects are the second most common feature of Alagille syndrome. The most frequent is narrowing of the pulmonary arteries, the vessels that carry blood from the heart to the lungs. This can range from mild narrowing that never requires treatment to more complex structural problems that need surgical repair. Some patients also have other congenital heart defects, including holes between heart chambers or problems with heart valves. A cardiac evaluation is a standard part of the workup for anyone suspected of having the syndrome.
Other Organ Systems Involved
Because Notch signaling is important throughout development, the effects of Alagille syndrome reach beyond the liver and heart.
- Skeleton: Many patients have butterfly-shaped vertebrae, a distinctive finding on spine X-rays where the bones of the spinal column appear split down the middle. This is usually painless and doesn’t cause structural problems, but it’s a useful clue for diagnosis.
- Eyes: A condition called posterior embryotoxon, a subtle ring of opacity at the edge of the cornea, is found in a large percentage of patients. It typically doesn’t affect vision and can only be seen during a specialized eye exam.
- Face: People with Alagille syndrome often share a recognizable set of facial features: a broad, prominent forehead, deep-set eyes, and a small, pointed chin. These features become more apparent with age and are particularly noticeable in childhood.
- Kidneys: Some patients develop kidney abnormalities ranging from small structural differences to more significant problems with kidney function.
- Blood vessels: There is an increased risk of abnormalities in blood vessels throughout the body, including in the brain. Vascular events, while uncommon, are one of the more serious potential complications.
How It’s Diagnosed
Diagnosis has historically relied on clinical criteria: identifying a combination of bile duct paucity on liver biopsy plus involvement of multiple organ systems (heart, skeleton, eyes, face). A child showing cholestasis along with characteristic findings in at least three of these areas would typically meet the clinical threshold. The challenge is that the full picture may not be present in infancy, and milder cases can be missed entirely.
Genetic testing has transformed the diagnostic process. Identifying a JAG1 or NOTCH2 mutation confirms the diagnosis regardless of how many clinical features are present. This is especially valuable for infants who haven’t yet developed the full spectrum of findings, or for family members with subtle or incomplete presentations. Before molecular testing was available, the estimated incidence was only 1 in 70,000 births, roughly half the true rate now understood to be closer to 1 in 30,000.
Managing Cholestatic Itching
For many patients and families, the itching caused by bile buildup is the symptom that most affects quality of life. It can be constant, severe, and resistant to standard anti-itch medications. Treatment focuses on reducing the amount of bile acids circulating in the blood.
A newer class of medications called IBAT inhibitors works by blocking the reabsorption of bile acids in the gut, essentially acting as a medical version of surgically rerouting bile. In clinical trials, these drugs significantly lowered bile acid levels in the blood and improved itching, xanthomas, and overall growth. Maralixibat (brand name Livmarli) was approved in September 2021 for cholestatic itching in Alagille syndrome patients one year of age and older. It was the first medication specifically approved for this use. A second drug in the same class, odevixibat, is currently in Phase 3 trials for Alagille syndrome after receiving approval for a related condition.
Before these medications became available, surgical biliary diversion (a procedure that reroutes bile flow away from the gut to reduce reabsorption) was sometimes used. However, research has shown that patients who underwent this surgery had a 2.5-fold greater risk of eventually needing a liver transplant or dying compared to those managed without it. This may reflect the fact that surgical diversion was typically reserved for the most severe cases rather than that the surgery itself worsened outcomes, but the finding has made medical alternatives increasingly preferred.
Liver Transplant and Long-Term Outlook
Not everyone with Alagille syndrome will need a liver transplant. Some patients see their liver disease stabilize or even improve over time, particularly if bilirubin levels trend downward in early childhood. Others progress to cirrhosis or develop complications severe enough to require transplantation.
The decision to pursue a transplant depends on several factors: the degree of liver failure, the severity of itching that hasn’t responded to other treatments, and the impact on growth and development. Because Alagille syndrome affects multiple organs, transplant teams need to evaluate heart function and vascular anatomy carefully before surgery. Outcomes after liver transplant are generally good when patients are selected appropriately, and transplantation can resolve cholestasis-related symptoms like itching and xanthomas.
Growth is a persistent concern. Poor bile flow impairs the absorption of fats and fat-soluble vitamins (A, D, E, and K), so children with Alagille syndrome often need supplementation and close nutritional monitoring. With adequate support, many patients reach adulthood and live independently, though the multi-organ nature of the condition means ongoing medical follow-up remains important throughout life.